Evaluating Bronchodilator Response in Patients With Bronchiectasis
Bronchiectasis, Cystic Fibrosis, Primary Ciliary Dyskinesia
About this trial
This is an interventional diagnostic trial for Bronchiectasis focused on measuring Bronchodilator response
Eligibility Criteria
Inclusion Criteria: Patients with bronchiectasis confirmed by CT scan No recent pulmonary exacerbation as determined by prescription of systemic antibiotics in 7 days prior to BDR testing No use of long-acting beta agonists (LABA) 12 hours before BDR testing or short acting beta agonist (SABA) 4 hours before testing Exclusion Criteria: Patients under 5 years of age Patients incapable to perform proper spirometry
Sites / Locations
- Rambam Health CampusRecruiting
Arms of the Study
Arm 1
Arm 2
Other
Other
Salbutamol first
Placebo First
Individuals included in this arm will receive 4 puffs of Salbutamol prior to the second set of spirometry testing, and 4 puffs of Placebo prior to the third set of spirometry.
Individuals included in this arm will receive 4 puffs of placebo prior to the second set of spirometry testing and 4 puffs of Salbutamol prior to the third set of spirometry testing.